Finance

Lists
Q3 2026 earnings • released • EPS beat +3.63% • Revenue beat +1.81%
See results
QGEN:NYSE
Qiagen NV
$50.33
-1.04%
(-0.53) 1D
$50.40
+0.14% (+0.070)
After hours
Closed: Nov 6, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for QGEN...
Open
$50.42
High
$50.50
Low
$50.26
Mkt. cap
10.39B
Avg. vol.
4.97M
Volume
3.39M
Dividend
0.70%
Quarterly dividend
$0.09
Ex-dividend date
Jul 7, 2026
P/E ratio
25.89
52-wk high
$57.82
52-wk low
$32.53
EPS
$1.94
Beta
0.57
Shares outstanding
206.50M
No. of employees
5K
Open
$50.42
High
$50.50
Low
$50.26
Mkt. cap
10.39B
Avg. vol.
4.97M
Volume
3.39M
Dividend
0.70%
Quarterly dividend
$0.09
Ex-dividend date
Jul 7, 2026
P/E ratio
25.89
52-wk high
$57.82
52-wk low
$32.53
EPS
$1.94
Beta
0.57
Shares outstanding
206.50M
No. of employees
5K
News stories
From web sources and news partners
Profile
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer. Wikipedia
About Qiagen NV
CEOThierry Bernard
Employees5.4K
FoundedNov 29, 1984
HeadquartersVenlo, Limburg, Netherlands
SectorHealth Care
Industry-
Websiteqiagen.com
Analyst
Recommendation
Action
Price target
Projected
Date
No analyst ratings found.
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.65 / $0.63
+3.63%beat
Revenue / Est. (USD)
547.87M / 538.14M
+1.81%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
540.42M
492.32M
535.04M
547.87M
Cost of goods sold
173.92M
168.83M
181.97M
181.11M
Cost of revenue
173.92M
168.83M
181.97M
181.11M
Research and development expenses
47.24M
48.26M
50.43M
53.94M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
153.88M
142.39M
146.77M
146.13M
Operating expense
218.30M
206.24M
212.22M
214.72M
Total operating expenses
392.22M
375.06M
394.19M
395.83M
Operating income
148.20M
117.26M
140.85M
152.04M
Other non operating income
-133.00K
193.00K
-35.00K
-431.00K
EBT including unusual items
109.17M
85.83M
132.10M
132.31M
EBT excluding unusual items
157.94M
118.66M
140.05M
151.88M
Income tax expense
1.34M
17.79M
28.70M
26.65M
Effective tax rate
1.23%
20.72%
21.73%
20.14%
Other operating expenses
-
-
-
-
Net income
107.83M
68.04M
103.40M
105.66M
Net profit margin
19.95%
13.82%
19.33%
19.29%
Earnings per share
0.62
0.54
0.62
0.65
Interest and investment income
20.00M
10.56M
9.36M
10.75M
Interest expense
-10.14M
-11.05M
-10.02M
-10.49M
Net interest expenses
9.86M
-489.00K
-661.00K
266.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
179.60M
168.47M
191.40M
205.13M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps